Key result
Continuous beta-blockers linked to ~49% lower MACE vs discontinuous therapy in post-AMI patients without HF.
Why the study?
The duration of beta-blocker therapy in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction remains unclear.
Does continuous beta-blocker therapy reduce cardiac death and MACE in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction?
Cohort (n=1,483)
Yes
Does continuous beta-blocker therapy reduce cardiac death and MACE in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction?
Continuous beta-blocker therapy for ≥6 months after AMI in patients without HF or LV dysfunction is associated with a reduced risk of MACE, unstable angina, and recurrent MI.
Observational association supports beta-blocker continuation post-AMI without HF; leaves open need for RCTs to confirm MACE benefit.
BACKGROUND: The duration of beta-blocker therapy in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI) is unclear. HYPOTHESIS: Continuous beta-blocker therapy is associated with an improved prognosis. METHODS: This is a prospective, multicenter, cohort study. One thousand four hundred and eighty-three patients eventually met the inclusion criteria. The study groups included the continuous beta-blocker therapy group (lasted ≥6 months) and the discontinuous beta-blocker therapy group (consisting of the no-beta-blocker therapy group and the beta-blocker therapy <6 months group). The inverse probability treatment weighting was used to control confounding factors. The study tried to learn the role of continuous beta-blocker therapy on outcomes. The median duration of follow-up was 13.0 months. The primary outcomes were cardiac death and major adverse cardiovascular events (MACE). The secondary outcomes were all-cause death, stroke, unstable angina, rehospitalization for HF, and recurrent myocardial infarction (MI). RESULTS: Compared with discontinuous beta-blocker therapy, continuous beta-blocker therapy was associated with a reduced risk of unstable angina, recurrent MI, and MACE (hazard ratio [HR]: 0.51; 95% CI: 0.32-0.82; p = 0.006); but this association was not available for cardiac death (HR: 0.57; 95% CI: 0.24-1.36; p = 0.206). When compared to the subgroups of no-beta-blocker therapy and beta-blocker therapy <6 months, respectively, continuous beta-blocker therapy was still observed to be associated with a reduced risk of unstable angina, recurrent MI, and MACE. CONCLUSIONS: Continuous beta-blocker therapy was associated with a reduced risk of unstable angina or recurrent MI or MACE in patients without HF or left ventricular systolic dysfunction after AMI.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2022) conducted a cohort in Acute myocardial infarction without heart failure or left ventricular systolic dysfunction (n=1,483). Continuous beta-blocker therapy (≥6 months) vs. Discontinuous beta-blocker therapy (no therapy or <6 months) was evaluated on Major adverse cardiovascular events (MACE) (HR 0.51, 95% CI 0.32-0.82, p=0.006). Continuous beta-blocker therapy for ≥6 months reduced the risk of major adverse cardiovascular events by 49% (HR 0.51) compared to discontinuous therapy in patients without heart failure after AMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: